Zanthoxylum nitidum (Roxb.) DC (Rutaceae) is a traditional medicine used for the treatment of various diseases like toothache, gingivitis, fever, colic vomiting, diarrhea, and cholera. Three new alkaloids, zanthocadinanine C (1), 7-methoxy-8-demethoxynitidine (2), and zanthonitiside I (3) were isolated from the stems and twigs of Z. nitidum. Their structures were determined on the basis of extensive spectroscopic, including 1-dimensional and 2-dimensional nuclear magnetic resonance and mass spectroscopy data. Compounds 1-3 were evaluated for cytotoxic activity against 5 human cancer cell lines, KB, MCF-7, LNCaP, HepG-2, and LU-1. Compound 2 showed significant cytotoxic activity against all tested human cancer cell lines with IC 50 values ranging from 10.3 to 12.6 µM.
Zanthoxylum nitidum (Roxb.) DC. (Rutaceae) is a scandent prickly shrub distributed in the Molucca Islands, New Guinea, South China, and Vietnam. In folk medicine, its roots have been used to promote blood circulation, dissipate blood stasis, and cure snake bite; leaves and stems have been used to treat toothache, sore throat, cough, and fever. Previous phytochemical investigations of this plant led to the isolation of phenanthridine alkaloids, [1] [2] [3] quinolines, 4 phenylpropanoids, 5 lignans, and coumarins. [4] [5] [6] These compounds exhibited anti-virus, 7 anti-inflammatory, 8, 9 and anti-cancer activities. [4] [5] [6] [7] [8] [9] [10] This paper reports three new alkaloids from Z. nitidum. In addition, these compounds were also evaluated for cytotoxic activity against 5 human cancer cell lines, KB, MCF-7, LNCaP, HepG2, and LU-1.
Compound 1 was obtained as a yellowish amorphous powder. Its molecular formula was deduced to be C 36 H 41 O 4 by high resolution-electrospray ionization mass spectrometry (HR-ESI-MS) analysis from the ion at m/z 552. 3108 Figure 2 , Supplementary data) between H-1 (δ H 7.09) and C-3 (δ C 147.7)/C4a (δ C 127.6); H-4 (δ H 7.53) and C-2 (δ C 147.4)/C12a (δ H 131.1) indicated the location of a methylenedioxy group at C-2 and C-3. The HMBCs between H-6 (δ H 4.61) and C-7 (δ C 145.9); between H-9 (δ H 6.93)/H-10 (δ H 7.54) and C-8 (δ C 152.1); between methoxy (δ H 3.94)/(δ H 3.92) and C-7 (δ C 145.9)/C-8 (δ C 152.1) proved the positions of the two methoxy groups to be at C-7 and C-8. The position of the N-methyl group was also confirmed by the observation of HMBC cross peaks from N-methyl (δ H 2.60) to C-4b (δ C 140.2) and C-6 (δ C 55.8). Thus, this part of the alkaloid was determined to be dihydrochelerythrine. 3 The HMBCs from H-11ʹ (δ H 2.00 and 2.07) to C-3ʹ (δ C 13 C NMR and distortionless enhancement by polarization transfer spectra of 2 exhibited the signals of 10 non-protonated carbons, 7 methines, 1 methylene, and 3 methyl carbons. Analysis of the 1 H-and 13 C-NMR data indicated the structure of 2 to be similar to that of nitidine, except for the movement of the methoxy group from C-8 to C-7. 11 In the HMBC spectrum, methylenedioxy protons (δ H 6.02) showed long-range correlations with C-2 (δ C 148.7) and C-3 (δ C 148.8) indicating that the methylenedioxy was linked to C-2 and C-3. The HMBCs between two methoxy groups (δ H 4.18)/(δ H 4.11) and C-7 (δ C 145.4)/C-9 (δ C 150.6), respectively, proved the position of the two methoxy groups at C-7 and C-9. The position of the N-methyl group was confirmed by HMBCs from methyl (δ H 5.00) to C-4a (δ C 120.1) and C-6 (δ C 150.8) (Figure 2) . Consequently, the new structure 2 was assigned to 7-methoxy-8-demethoxynitidine.
The molecular formula of 3 was determined to be C 21 , were attributed to a β-glucopyranosyl; the remaining signals were attributed to an isoprene quinoline alkaloid. 12 In addition, 2D-NMR experiments completed the structure elucidation (Figure 1 β-d-glucopyranoside (δ C 13.1), 13 and one having an E configuration, hydroxyostholeepoxide (δ C 21.8).
14 Consequently, the structure of 3 was elucidated and named zanthonitiside I.
Compounds 1-3 were evaluated for cytotoxic activity against 5 human cancer cell lines, KB, MCF-7, LNCaP, HepG-2, and LU-1. Significant cytotoxic activity was shown against all 5 with IC 50 values ranging from 10.3 to 12.6 µM, compared with those of the positive control, ellipticine (IC 50 ranging from 1.3 to 1.7 µM). Compounds 1 and 3 did not show any cytotoxic activity (IC 50 > 100 µM) (Table 1) . Thus, alkaloid 2 may become a target molecule for the treatment of cancers.
Experimental

General
Optical rotations were determined on a Jasco DIP-370 automatic polarimeter. The NMR spectra of compounds 1 and 2 were recorded using a Bruker DRX 500 spectrometer; NMR spectra of compound 3 were recorded using a 400-MR spectrometer. The HR-ESI-MS were obtained using an Agilent 6550 iFunnel QTOF LC/MS system. Preparative HPLC was carried out using an AGILENT 1200 HPLC system. Column chromatography was performed on either silica-gel (Kieselgel 60, 70-230 mesh and 230-400 mesh, Merck) or RP-18 resins (30-50 μm, Fuji Silysia Chemical Ltd.). For thin layer chromatography (TLC), pre-coated silica-gel 60 F254 (0.25 mm, Merck) and RP-18 F254S (0.25 mm, Merck) plates were used.
Plant Materials
The stems and twigs of Z. nitidum were collected at Nahang, Tuyen Quang, Vietnam in February 2016, and identified by Dr Nguyen The Cuong, Institute of Ecology and Biological Resources, VAST. A voucher specimen (XT-01/NaHang) was deposited at the Institute of Natural Products Chemistry, VAST.
Extraction and Isolation
The dried powdered stems and twigs of Z. nitidum (5.0 kg) were extracted with hot methanol 3 times (each 10 L, 2 days) at 50°C and then the solvent was removed in vacuo to yield the methanol extract (250.0 g). This was suspended in H 2 O (1.5 L) and successively partitioned with n-hexane, chloroform, and ethyl acetate (EtOAc) to yield n-hexane (ZN1, 80.0 g), chloroform (ZN2, 65.0 g), and EtOAc (ZN3, 26.0 g) residues, and a water layer (ZN4). ZN1 was chromatographed on a silica gel column and eluted with a solvent system of n-hexane:EtOAc (100:0, 70:1, 50:1, 30:1, 10:1, and 1:1, v/v) to give 6 fractions, ZN1A-ZN1F. ZN1C was repeatedly chromatographed on a silica gel column, eluting with n-hexane:EtOAc (10:1, v/v) to give 5 smaller fractions, ZN1C1-ZN1C5. Compound 1 (10 mg) was obtained from ZN1C3 fraction by using a RP-18 column and eluting with acetone:water (4:1, v/v). ZN1C5 was chromatographed on a silica gel column with dichloromethane/methanol (20:1, v/v), and then a RP-18 column eluting with methanol: water (4: 1, v/v) to yield compound 2 (7 mg). ZN1E was loaded onto a silica gel column and eluted with dichloromethane: methanol (10:1, v/v) to give 3 fractions, ZN1E1-ZN1E3. Compound 3 (4.0 mg) was obtained from ZN1E2 using an HPLC column (J'sphere, ODS H-80, 250 × 20 mm) with a flow rate of 3 mL/min eluting with 25% acetonitrile.
Zanthocadinanine C (1)
Yellowish amorphous powder. 
Zanthonitiside I (3)
Acid Hydrolysis
A solution of compound 3 (2 mg) in 3% HCl (4 mL, each) was heated under reflux for 4 hours. Then, the solution was evaporated under reduced pressure and the residue subjected to TLC analysis. 
Cytotoxic Assays
The KB (human oral carcinoma), MCF-7 (human breast carcinoma), LNCaP (human prostate cancer), HepG-2 (human hepatocellular carcinoma), and LU-1 (human lung carcinoma) cell lines were obtained from Milan University, Italy and Hawaii University, USA. Effects of compounds 1-3 on the growth of human cancer cells were determined by measuring the cytotoxic activity using the sulforhodamine B (SRB) assay. The cancer cell lines were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin at 37°C in a humidified 5% CO 2 atmosphere. Exponentially growing cells were used throughout the experiments. The SRB assays were performed as follows: human cancer cells (1 × 10 5 cells/mL) were treated for 2 days with 1, 10, 20, 50, and 100 µM of each compound and ellipticine. All the experiments were performed 3 times. The inhibitory concentration of 50% (IC 50 ) was determined for each compound. 
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